PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger

Summary

• VanEck Pharmaceutical ETF holds a mixed outlook due to high fees and tariff risks, warranting a hold rating despite strong top holdings.
• PPH's top holdings like Eli Lilly and Johnson & Johnson have diversified revenue streams and U.S. manufacturing investments, mitigating tariff impacts.
• PPH has underperformed compared to broader healthcare ETFs like VHT and XLV, which offer better diversification and lower expense ratios.
• While PPH offers stability and a high dividend yield, broader healthcare funds may provide superior long-term gains due to lower risk and better performance.

J Studios

Investment Thesis

VanEck Pharmaceutical ETF (NASDAQ:PPH) warrants a hold rating due to mixed outlook factors impacting the fund. While PPH’s top holdings will likely avoid significant impacts from tariff policies due to their diversified revenue streams and

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

This article is exclusive to Seeking Alpha. No duplication or reproduction of this article is allowed without consent of Seeking Alpha and the author. This article should not be misconstrued as individual financial advice. Always conduct your own due diligence prior to investing.